Renhong Tang

发表

Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir

Gengfu Xiao, Yan Zhang, H. Su, 2023, Nature communications.

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.

Ye-ming Wang, Xiaoying Gu, Jiuyang Xu, 2024, New England Journal of Medicine.

A First-In-Human Phase 1 Study of Simnotrelvir, a 3CL-like Protease Inhibitor for Treatment of COVID-19, in Healthy Adult Subjects.

Lei-ke Zhang, Bufan Yao, Xin-mei Yang, 2023, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.